

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 6, 2023

Comera Life Sciences Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

1-41403
(Commission
File Number)

87-4706968
(IRS Employer
Identification No.)

**12 Gill Street
Suite 4650
Woburn, Massachusetts**
(Address of principal executive offices)

01801
(Zip Code)

Registrant's telephone number, including area code: (617) 871-2101

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CMRA	The Nasdaq Stock Market LLC
Warrants	CMRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Comera Life Sciences Holdings, Inc. (the "Company") from time to time presents at various industry and other conferences and provides summary business information. A copy of the slide presentation that will be used by representatives of the Company in connection with such presentations (the "Corporate Presentation") is attached to this Current Report on Form 8-K as Exhibit 99.1. The Corporate Presentation is current as of January 6, 2023, and the Company disclaims any obligation to correct or update this material in the future.

The information in the Corporate Presentation attached as Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation current as of January 6, 2023
104	Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 6, 2023

COMERA LIFE SCIENCES HOLDINGS, INC.

By: /s/ Michael Campbell

Name: Michael Campbell

Title: Executive Vice President and Chief Financial Officer

Corporate Presentation

January 2023



Comera
LIFE SCIENCES



This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by forward-looking words such as “may,” “might,” “could,” “will,” “would,” “should,” “expect,” “possible,” “potential,” “anticipate,” “contemplate,” “believe,” “estimate,” “plan,” “predict,” “project,” “intends,” and “continue” or similar words, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: risks that the recently completed business combination disrupts the Company’s current plans and ability to retain its employees; the Company’s ability to maintain the listing of its securities on the Nasdaq Capital Market; the effect of the COVID-19 pandemic on the Company’s business; the price of the Company’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company’s business and changes in the capital structure; the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company’s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; general economic conditions; and other risks and uncertainties indicated in the Quarterly Report on Form 10-Q filed with the SEC on November 14, 2022 under “Risk Factors” and in other filings that have been made or will be made with the SEC.

Accordingly, nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved, and any forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.



Leading a compassionate new era in medicine.

- True medical advances are inspired by compassion
- Our technology transforms antibody therapies from IV to self-administered, SQ forms
- The **freedom of self injectable care** allows patients to fully realize the potential of their lives

Near-Term Milestones

- Partnerships yield near-term licensing fees; IND filing milestones within ~2 years

Lower-Risk Development

- Focus on reformulation of existing drugs

Multiple Shots on Goal

- SQore™ technology can be applied across multiple partnership and pipeline programs

Capital Efficient

- Business model characterized by low operating cost and development spend

Innovative SQore™ Technology Enables Self Administration of Biologics



- >\$30M invested in building and developing platform technology
- ~10 years of research to develop and optimize SQore platform
- Robust platform tested across 20 different mAbs

SQore technology does not alter the structure or physical form of antibodies in solution, reducing drug product development uncertainty, time and expense vs. some other approaches

SQore™ approach

- SQore excipients do not bind to antibody
- No structural or chemical change to antibody
- Antibody remains as a true solution with no particulates
- No expected impact to mAb absorption or distribution after SQ administration

Other viscosity reduction approach examples

- Alteration of protein conformation or chemistry (e.g. dehydration, resuspension)
- Alteration of delivered solution (e.g. non-aqueous microparticle suspension)
- Impact to mAb absorption or distribution after SQ administration potentially unknown

Approaches that either alter mAb structure/function or the physical form of the antibody itself raise new scientific issues that may increase development risk, cost and timeline

Dual Growth Pillars: Partnerships and Pipeline

Comera's growth driven by utilizing our SQore platform to create value through partnerships with external innovators as well as developing our own reformulated SQ assets



Learnings shared across pharma partnerships and internal product development

Feasibility Evaluation

Revenue generating research collaboration to assess feasibility

License Option Exercise

Potential **\$multi-million** upfront payment to license SQore technology

Milestones


Potential **\$multi-million** payments upon achievement of key development milestones

Royalties

Potential **single to mid teen %** royalty on product sales

Biopharma Out-Licensors are Receiving Larger Upfront Cash and Equity Investment Deals

High-Dollar In-Licensing: Share of Deals by Range of Upfront Cash & Equity



Source: DealForma.com database. Financials based on disclosed figures. Data through 4/7/2022.

CLS-001 (SQ Vedolizumab): Best-in-Class Formulation Comera LIFE SCIENCES


CLS-001 is a multibillion-dollar product opportunity bringing differentiated value to improve the lives of patients with a self-administered SQ formulation having reduced dosing frequency

Program	SQ formulation of vedolizumab
Therapeutic Area	IBD <i>Ulcerative colitis and Crohn's disease</i>
Development Status	Formulation development
Competition	No SQ currently in US <i>Estimated SQ Entyvio approval 2024</i>
Differentiation	Once monthly SQ dosing vs. every 2 weeks
Peak Annual Sales Potential	~\$2B

Blockbuster product - large conversion opportunity



WW Sales (2021): **\$4B**
Estimated Peak (2026+): **\$7.5-9.0B**



Source : L.E.K market research and analysis, January 2022; EvaluatePharma; Biosimilardevelopment.com; Parrish (2020); Company website; Cowen (09.2021); SVB Leerink (10.2021); H.C. Wainwright (10.2021); Jefferies (07.2021); https://www.takeda.com/4ada11/siteassets/system/investors/report/quarterlyannouncements/fy2022/qr2022_q2_p01_en.pdf

Biologics Market is Massive and Growing Rapidly

Global biologics market valued at ~\$383B in 2022 and is expected to grow at an 8.8% CAGR through 2032¹

7 of the top 10 global medicines are biologics²

Products across all major therapeutic indications

Significant market opportunity for formulation improvements

mAb therapies at the vanguard of cutting-edge biomedical technology and driving the next generation of treatments



1. Source: <https://www.globenewswire.com/news-release/2022/08/09/2494541/0/en/The-Global-Biologics-market-is-projected-to-grow-at-a-CAGR-of-8-82-By-2032-Visiongain-Reports-Ltd.html>

2. Source: <https://www.globenewswire.com/news-release/2019/01/11/1690388/0/en/Global-Biologics-Outsourcing-Market-2018-2027-In-2017-7-out-of-10-Blockbuster-Drugs-were-Biologics-Outnumbering-Small-Molecule-Drugs.html>

- Most biologics administered intravenously, with significant limitations

- Self-administered SQ therapy has multiple potential benefits

- High viscosity is a significant hurdle to formulating biologics to SQ



SQore™: Validated by Scientific Peer-Review

Caffeine-based lead SQore excipient proven in externally validated, rigorous scientific evaluation to achieve all desired target parameters for a viable SQ formulation


- Lead SQore excipient, caffeine, used to show SQ formulation proof of concept for two leading mAbs




- Significant viscosity reduction
- No effect on mAb stability
- No loss of biological activity



Caffeine-based **SQore™** Excipient Optimized to Lower Viscosity for Several Biologics



Infliximab formulated in a 20 mM phosphate-acetate buffer at pH 6.0 (control) and in the presence of 75 mM caffeine, 100 mM ArgHCl, or 100 mM NaCl



Ipilimumab formulated in Yervoy commercial formulation vehicle (Comm.) and PBS with or without 75 mM caffeine

3 Patent families; 12 issued

- Viscosity Reduction
- Stabilizer
- Process enhancement





>35 Patents Pending

Broad geographical reach:

- US
- EU
- APAC
- Canada



- **Innovation focused on novel method of use for excipient molecules**
 - Viscosity reduction
 - Stability enhancement
 - Enhancement of processing efficiency
 - SQore computational prediction algorithms
- **New formulation IP generated with SQore technology provides substantial value**
 - Compelling commercial proposition of lifecycle extension for partners drives significant interest
 - Potential for extension of franchise patent protection: ~20 years



Partnering Strategy

Selective focus on high-value collaborations with near-term milestone value

- Late-stage clinical programs and/or commercialized assets
- Programs with significant commercial potential
- High patient quality-of-life impact with availability of self-injectable formulation
- Emphasis on long-term value creation (milestone payments, royalties), if collaboration successful
- Companies with broad mAb portfolio
- Potential interest in licensing and acquiring Comera's internal assets at downstream stages of development

Current Partnerships

Partnership #1 Regeneron

- Leading US biotechnology company
- High-priority assets in development
- Recently extended and broadened
- Includes a right to negotiate license after further technical evaluation complete

Partnership #2 Undisclosed

- Top 10 global pharma company
- Drug commercialized globally, currently the largest biologic drug by revenue to Company (top two overall)
- Option to license after further technical evaluation complete

Partnership #3 Intas Pharmaceuticals Ltd.

- Intas Pharmaceuticals is a leading, vertically-integrated pharmaceutical company.
- Development of a biosimilar product in oncology
- Option to license after further technical evaluation complete

Leveraging SQore to Build Our Own SQ Pipeline

Development focus is utilizing SQore platform to reformulate existing, commercially proven IV biologics to SQ forms, then out-licensing to partners after IND filing

- Multiple asset opportunities
- Short-term development
- Low capital intensity
- Lower risk vs. novel program
- Near-term return



Multiple SQ Pipeline Opportunities Exist

*We have identified several other opportunities that fit the profile of our development focus:
SQ reformulation of multi-billion dollar IV biologic products using the SQore platform*

	Therapeutic Area	Peak Market Size
Opportunity #1	Oncology	~\$15B
Opportunity #2	Oncology	~\$10B
Opportunity #3	Inflammation	~\$1B
Opportunity #4	Oncology	~\$3B
Opportunity #5	Inflammation	~\$2B
Opportunity #6	Oncology, Inflammation	~\$4B

Source: L.E.K market research and analysis, January 2022

Experienced and Accomplished Management Team



Jeffrey S. Hackman
Chairman and Chief Executive Officer



Neal I. Muni, MD, MSPH
Chief Operating Officer



Robert Mahoney, Ph.D.
Chief Scientific Officer



Michael Campbell
Chief Financial Officer



Janice Marie McCourt
Chief Business Officer



Successful track record of drug development and life sciences operating expertise

Near-Term Milestones

- Partnerships yield near-term licensing fees; IND filing milestones within ~2 years

Lower-Risk Development

- Focus on reformulation of existing drugs

Multiple Shots on Goal

- SQore™ technology can be applied across multiple partnership and pipeline programs

Capital Efficient

- Business model characterized by low operating cost and development spend
- 

Thank you!

Investor Contact

John Woolford

ICR Westwicke

John.Woolford@westwicke.com

Press Contact

Jon Yu

ICR Westwicke

comerapr@westwicke.com

12 Gill Street, Suite 4650

Woburn, MA 01801, USA

comeralifesciences.com

